Discovery of Cyclin-dependent Kinase Inhibitor, CR229, Using Structure-based Drug Screening

  • Kim, Min-Kyoung (Department of Medical Genetics, College of Medicine, Hanyang University) ;
  • Min, Jae-Ki (Department of Molecular Biology and Pharmacology, C&C Research Laboratories) ;
  • Choi, Bu-Young (Department of Molecular Biology and Pharmacology, C&C Research Laboratories) ;
  • Lim, Hae-Young (Department of Medical Genetics, College of Medicine, Hanyang University) ;
  • Cho, Youl-Hee (Department of Medical Genetics, College of Medicine, Hanyang University) ;
  • Lee, Chul-Hoon (Department of Medical Genetics, College of Medicine, Hanyang University)
  • 발행 : 2007.10.30

초록

To generate new scaffold candidates as highly selective and potent cyelin-dependent kinase (CDK) inhibitors, structure-based drug screening was performed utilizing 3D pharmacophore conformations of known potent inhibitors. As a result, CR229 (6-bromo-2,3,4,9-tetrahydro-carbolin-1-one) was generated as the hit-compound. A computational docking study using the X-ray crystallographic structure of CDK2 in complex with CR229 was evaluated. This predicted binding mode study of CR229 with CDK2 demonstrated that CR229 interacted effectively with the Leu83 and Glu81 residues in the ATP-binding pocket of CDK2 for the possible hydrogen bond formation. Furthermore, biochemical studies on inhibitory effects of CR229 on various kinases in the human cervical cancer HeLa cells demonstrated that CR229 was a potent inhibitor of CDK2 ($IC_{50}:\;3\;{\mu}M$), CDKI ($IC_{50}:\;4.9\;{\mu}M$), and CDK4 ($IC_{50}:\;3\;{\mu}M$), yet had much less inhibitory effect ($IC_{50}:>20\;{\mu}M$) on other kinases, such as casein kinase 2-${\alpha}1$ (CK2-${\alpha}1$), protein kinase A (PKA), and protein kinase C (PKC). Accordingly, these data demonstrate that CR229 is a potent CDK inhibitor with anticancer efficacy.

키워드

참고문헌

  1. Choi, Y. H., W. H. Lee, K. Y. Park, and L. Zhang. 2000. p53- independent induction of p21 (WAF1/CIP1), reduction of cyclin B1 and G2/M arrest by the isoflavone genistein in human prostate carcinoma cells. Cancer Sci. 91: 164-173 https://doi.org/10.1111/j.1349-7006.2000.tb00928.x
  2. Davis, S. T., B. G. Benson, H. N. Bramson, D. E. Chapman, S. H. Dickerson, K. M. Dold, D. J. Eberwein, M. Edelstein, S. V. Frye, R. T. Gampe, R. J. Grifffen, P. A. Harris, A. M. Hassell, W. D. Holmes, R. N. Hunter, V. B. Knick, K. Lackey, B. Lovejoy, M. J. Luzzio, D. Murray, P. Parker, W. J. Rocgue, L. Shewchuk-Chapman, J. M. Veal, D. H. Walker, and L. F. Kuyper. 2001. Prevention of chemotherapyinduced alopecia in rats by CDK inhibitors. Science 291: 134-137 https://doi.org/10.1126/science.291.5501.134
  3. Desjarlais, R. L. 1997. Generation and use of threedimensional databases for drug discovery, pp. 73-104. In P. S. Charifson (ed.), Practical Application of Computer-aided Drug Design. Marcel Dekker, New York, U.S.A
  4. Doerig, C., L. Meijer, and J. C. Mottram. 2002. Protein kinases as drug targets in parasitic protozoa. Trends Parasitol. 18: 366-371 https://doi.org/10.1016/S1471-4922(02)02321-8
  5. Gray, N., L. Detivaud, C. Doerig, and L. Meijer. 1999. ATPsite directed inhibitors of cyclin-dependent kinases. Curr. Med. Chem. 6: 859-875
  6. Honma, T., K. Hayashi, T. Aoyama, N. Hashimoto, T. Machida, K. Fukasawa, T. Iwama, C. Ikeura, M. Ikuta, I. Suzuki-Takahashi, Y. Iwasawa, T. Hayama, S. Nishimura, and H. Morishima. 2001. Structure-based generation of a new class of potent Cdk4 inhibitors: New de novo design strategy and library design. J. Med. Chem. 44: 4615-4627 https://doi.org/10.1021/jm0103256
  7. Kakizaki, I., K. Ookawa, T. Ishikawa, M. Hayakari, T. Aoyagi, and S. Tsuchida. 2000. Induction of apoptosis and cell cycle arrest in mouse colon 26 cells by benastatin A. Cancer Sci. 91: 1161-1168 https://doi.org/10.1111/j.1349-7006.2000.tb00900.x
  8. Kawanishi, N., T. Sugimoto, J. Shibata, K. Nakamura, K. Masutani, M. Ikuta, and H. Hirai. 2006. Structure-based drug design of a highly potent CDK1,2,4,6 inhibitor with novel macrocyclic quinoxalin-2-one structure. Bioorg. Med. Chem. Lett. 16: 5122-5126 https://doi.org/10.1016/j.bmcl.2006.07.026
  9. Kim, H. J., J. H. Kim, C. H. Lee, and H. J. Kwon. 2006. Gentisyl alcohol, an antioxidant from microbial metabolite, induces angiogenesis in vitro. J. Microbiol. Biotechnol. 16: 475-479
  10. Kim, H. J. and H. J. Kwon. 2007. Synthesis and biological activity of fungal metabolite, 4-hydroxy-3-(3'-methyl-2'-butenyl)-benzoic acid. J. Microbiol. Biotechnol. 17: 543-545
  11. Kim, M. K., Y.-H. Cho, J. M. Kim, M. W. Chun, S. K. Lee, Y. Lim, and C.-H. Lee. 2005. Induction of apoptosis in human leukemia cells by MCS-C2 via caspase-dependent Bid cleavage and cytochrome c release. Cancer Lett. 223: 239-247 https://doi.org/10.1016/j.canlet.2004.10.045
  12. Knockaert, M., P. Greengard, and L. Meijer. 2002. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol. Sci. 23: 417-425 https://doi.org/10.1016/S0165-6147(02)02071-0
  13. Lim, H., M. K. Kim, Y.-H. Cho, J. M. Kim, Y. Lim, and C.-H. Lee. 2004. Inhibition of cell cycle progression and induction of apoptosis in HeLa cells by HY558-1, a novel CDK inhibitor isolated from Penicillium minioluteum F558. J. Microbiol. Biotechnol. 14: 978-984
  14. Lim, H., M. K. Kim, Y. Lim, Y.-H. Cho, and C.-H. Lee. 2006. Inhibition of cell-cycle progression in HeLa cells by HY52, a novel cyclin-dependent kinase inhibitor isolated from Bauhinia forficata. Cancer Lett. 233: 89-97 https://doi.org/10.1016/j.canlet.2005.03.002
  15. Lim, H., Y. Lim, Y.-H. Cho, and C.-H. Lee. 2006. Induction of apoptosis in the HepG2 cells by HY53, a novel natural compound isolated from Bauhinia forficata. J. Microbiol. Biotechnol. 16: 1262-1268
  16. Lim, H., H. L. Oh, and C.-H. Lee. 2006. Effect of Aralia continentalis root extract on cell proliferation and apoptosis in human promyelocytic leukemia HL-60 cells. J. Microbiol. Biotechnol. 16: 1399-1404
  17. Obaya, A. J. and J. M. Sedivy. 2002. Regulation of cyclin- CDK activity in mammalian cells. Cell. Mol. Life Sci. 59: 126-142 https://doi.org/10.1007/s00018-002-8410-1
  18. Osuga, H., S. Osuga, F. Wang, R. Fetni, M. J. Hogan, R. S. Stack, A. M. Hakim, J. E. Ikeda, and D. S. Park. 2000. Cyclin-dependent kinases as a therapeutic target for stroke. Proc. Natl. Acad. Sci. USA 97: 10254-10259
  19. Park, H. Y., M. K. Kim, S. I. Moon, Y.-H. Cho, and C.-H. Lee. 2006. Cell cycle arrest and apoptotic induction in LNCaP cells by MCS-C2, novel cyclin-dependent kinase inhibitor, through $p53/p21^{WAF1/CIP1}$ pathway. Cancer Sci. 97: 430-436 https://doi.org/10.1111/j.1349-7006.2006.00195.x
  20. Schang, L. M., A. Rosenberg, and P. A. Schaffer. 2000. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J. Virol. 74: 2107-2120 https://doi.org/10.1128/JVI.74.5.2107-2120.2000
  21. Shapiro, G. I. 2006. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24: 1770-1783 https://doi.org/10.1200/JCO.2005.03.7689
  22. Sherr, C. J. 1996. Cancer cell cycle. Science 274: 1672-1677 https://doi.org/10.1126/science.274.5293.1672
  23. Sherr, C. J. 1993. Mammalian G1 cyclins. Cell 73: 1059-1065
  24. Sherr, C. J. and J. M. Roberts. 1999. CDK inhibitors: Positive and negative regulators of G1-phase progression. Genes Dev. 13: 1501-1512 https://doi.org/10.1101/gad.13.12.1501
  25. Takizawa, C. G. and D. O. Morgan. 2000. Control of mitosis by changes in the subcellular location of cyclin-B1-CDK1 and Cdc25C. Curr. Opin. Cell Biol. 12: 658-665 https://doi.org/10.1016/S0955-0674(00)00149-6
  26. Vakser, I. A. and C. Aflalo. 1994. Hydrophobic docking: A proposed enhancement to molecular recognition techniques. Proteins 20: 320-329 https://doi.org/10.1002/prot.340200405
  27. Vulpetti, A., E. Casale, F. Roletto, R. Amici, M. Villa, and P. Pevarello. 2006. Structure-based drug design to the discovery of new 2-aminothiazole CDK2 inhibitors. J. Mol. Graph. 24: 341-348 https://doi.org/10.1016/j.jmgm.2005.09.012
  28. Wang, D., C. de la Fuente, L. Deng, L. Wang, I. Zilberman, C. Eadie, M. Healey, D. Stein, T. Denny, L. E. Harrison, L. Meijer, and F. Kashanchi. 2001. Inhibition of human immunodeficiency virus type 1 transcription by chemical cyclin-dependent kinase inhibitors. J. Virol. 75: 7266-7279 https://doi.org/10.1128/JVI.75.16.7266-7279.2001